| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYL12A |
| Uniprot No | P19105 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-171aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMSSKRTKTKTKKRPQRATSNVFAMFD QSQIQEFKEAFNMIDQNR DGFIDKEDLHDMLASLGKNPTDEYLDAMMN EAPGPINFTMFLTMFGEKLNGTDPEDVIRNAFACFDEEATGTIQE DYL RELLTTMGDRFTDEEVDELYREAPIDKKGNFNYIEFTRILKHGAKDKDD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYL12A重组蛋白的3篇示例参考文献(文献信息为虚构示例，实际需通过数据库查询)：
---
1. **文献名称**: "Recombinant MYL12A regulates actomyosin contractility in cancer cell migration"
**作者**: Chen L, et al.
**摘要**: 研究通过大肠杆菌系统表达并纯化MYL12A重组蛋白，发现其通过调控肌球蛋白II活性增强肿瘤细胞迁移能力，为靶向肿瘤转移提供了潜在机制。
2. **文献名称**: "Structural and functional analysis of MYL12A in non-muscle cells"
**作者**: Tanaka K, et al.
**摘要**: 利用哺乳动物细胞表达系统获得MYL12A重组蛋白，结合冷冻电镜解析其与MYH9的互作结构，揭示了其在细胞骨架重塑中的关键作用。
3. **文献名称**: "Optimization of MYL12A recombinant protein production for kinase activity assays"
**作者**: Wang Y, et al.
**摘要**: 通过优化原核表达条件提高MYL12A重组蛋白的溶解度与产量，并验证其作为Rho激酶下游底物的磷酸化特性，为体外信号通路研究提供工具。
---
注：以上文献为示例，实际引用需以PubMed、Google Scholar等平台检索为准。
MYL12A (Myosin Light Chain 12A), also known as MLC-2 or MLC2A, is a regulatory component of myosin II, a motor protein critical for cellular processes such as contraction, motility, and cytoskeletal organization. It belongs to the EF-hand calcium-binding protein family and functions as a light chain subunit that modulates myosin II’s ATPase activity and actin-binding capacity. MYL12A is ubiquitously expressed, with notable roles in smooth muscle contraction, cell division, and maintenance of cell shape. Its activity is tightly regulated by phosphorylation, particularly through Rho-associated kinase (ROCK) and myosin light chain kinase (MLCK), which influence cellular responses to mechanical and biochemical signals.
Recombinant MYL12A protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) to study its structure-function relationships and interactions within myosin II complexes. Researchers utilize it to investigate mechanisms underlying diseases linked to cytoskeletal dysregulation, such as hypertension, cancer metastasis, and neurological disorders. For instance, aberrant MYL12A expression has been associated with tumor cell invasion and cardiovascular pathologies, making it a potential biomarker or therapeutic target.
The recombinant form often includes tags (e.g., His-tag) for purification and detection, enabling in vitro assays like pull-down experiments, kinase activity studies, or structural analyses via crystallography. Its production bypasses challenges in isolating native MYL12A from tissues, ensuring high purity and consistency. Current research focuses on elucidating MYL12A’s role in mechanotransduction, cell signaling crosstalk, and its tissue-specific isoforms. Despite progress, questions remain about its differential regulation across cell types and pathological contexts, driving ongoing exploration into its molecular dynamics and therapeutic applications.
×
